DMP Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €38.00 |
| 52 Week High | €43.22 |
| 52 Week Low | €30.15 |
| Beta | 1.12 |
| 1 Month Change | 1.33% |
| 3 Month Change | 13.10% |
| 1 Year Change | -9.18% |
| 3 Year Change | -55.87% |
| 5 Year Change | -1.87% |
| Change since IPO | 46.15% |
Recent News & Updates
Dermapharm Holding SE's (ETR:DMP) P/E Is On The Mark
Dec 19
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17Recent updates
Dermapharm Holding SE's (ETR:DMP) P/E Is On The Mark
Dec 19Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively
Apr 29Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings
Feb 07Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly
Dec 15An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued
Nov 17Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
Aug 28Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price
Aug 01Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
May 29Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?
May 03Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear
Apr 04We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt
Feb 22Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Nov 17Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Aug 16Is Dermapharm Holding (ETR:DMP) A Risky Investment?
May 18Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?
Feb 17These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well
Nov 19Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Aug 21Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?
Jul 31Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?
May 03Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)
Apr 16Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly
Mar 25Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?
Mar 07Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?
Feb 15Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend
Jan 29Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Dec 24
The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More
Dec 07Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
Nov 18Shareholder Returns
| DMP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.8% | -2.5% | -2.6% |
| 1Y | -9.2% | -15.6% | 6.9% |
Return vs Industry: DMP exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: DMP underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| DMP volatility | |
|---|---|
| DMP Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DMP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DMP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,603 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Dermapharm Holding SE Fundamentals Summary
| DMP fundamental statistics | |
|---|---|
| Market cap | €2.05b |
| Earnings (TTM) | €90.59m |
| Revenue (TTM) | €1.17b |
22.6x
P/E Ratio1.7x
P/S RatioIs DMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMP income statement (TTM) | |
|---|---|
| Revenue | €1.17b |
| Cost of Revenue | €439.61m |
| Gross Profit | €734.32m |
| Other Expenses | €643.74m |
| Earnings | €90.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 62.55% |
| Net Profit Margin | 7.72% |
| Debt/Equity Ratio | 174.1% |
How did DMP perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield52%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dermapharm Holding SE is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Daniel Wendorff | Commerzbank AG |
| Fabian Piasta | Jefferies LLC |